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identify and communicate the
impacts of that research to the Aus-
tralian community, and to use the
findings as an evidence base to inform
and guide the NBCF’s future funding
strategies.
sive method for assessing returns
from research.10-13
The NBCF commissioned the
Health Economics Research Group
(HERG) at Brunel University to con-
duct a Payback study to record the
• scientific peer-reviewed publica-
tions as the central means of sharing
knowledge with the research com-
munity;
• dissemination of knowledge pro-
duced to academic and non-academic
audiences;Evaluation o
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Traditional approaches to evaluat-
ing the benefits of health and medical
research focus on impacts on know-
ledge production and the researchsystem. However, research funders in
Australia have increasingly sought to
demonstrate the wider benefits of
research, such as improved treat-
ments and health gains.7,8 This has
resulted in interest in developments
such as the Payback Framework,
which fuses traditional measures with
broader categorisations of the benefits
from health and medical research,9
and is internationally acknowledged
Methods
The Payback Framework9 was applied
to the portfolio of NBCF-funded
research from 1 January 1995 to 31
March 2012. Ethics approval was
obtained from Brunel University’s
Research Ethics Committee. Data
were collected and analysed in 2012
from March onwards.
Data were collected to measure the
publications. Seventy surveys (46%) reported career progression, and 185 
higher degrees were obtained or expected, including 121 PhDs. One hundred and 
one grants (66%) produced tools that built capacity across the research 
system, and research teams leveraged an additional $1.40 in funding for every 
dollar invested. Fifteen applied grants and one basic grant impacted on policy. 
Ten basic and four applied grants led to the development of drugs, prognostic 
tools or diagnostic technologies. Twenty applied and two basic grants led to 
changes in practice and behaviour of health care staff, consumers and the 
public, with further impacts anticipated. Case studies provided illustrations 
of high impact.
Conclusions:  NBCF’s strategy of investing in a mixed portfolio of research areas 
and mechanisms encouraged a broad range of impacts across all Payback 
categories. The impacts from basic research tended to focus on knowledge 
production and drug development; while applied research generated greater 
impacts within the other Payback categories. The funding of shared 
infrastructure stimulated impact across the research system.settings.5,6
board of 
pendent e
ment in he role of charities in sup-
porting health and medical
research is substantial. In
2011, Australia’s total federal, state
and non-government organisation
spending on cancer research projects,
programs and infrastructure was $300
million, of which $83 million was
awarded by major national cancer
research funding charities, including
$9 million by the National Breast
Cancer Foundation (NBCF).1 With
growing competition for the charity
dollar, it is becoming increasingly
important for medical research chari-
ties to demonstrate the outcomes or
benefits of the research that they fund
and to identify research strategies
that are most likely to produce future
benefits.2-4
The NBCF was established in 1994,
and by early 2012 had invested over
$81 million in over 300 Australian-
based research projects. The NBCF
seeks to invest in breast cancer
research that will have the greatest
impact, aiming to reduce the burden
of a breast cancer diagnosis for all
those living with or at high risk of
developing breast cancer, and their
families. All funds are raised from and
within the Australian community. The
NBCF’s research investment strategy
supports a commitment to funding
across the research continuum from
basic to applied research, and the
translation of research into clinical
 In early 2012, the NBCF’s
directors sought an inde-
valuation of its total invest-
breast cancer research to as the most widely used comprehen- impact of NBCF research in terms of:
f the impact of National Breast 
dation-funded research
T
earch
Objective:  To evaluate the impact of the National Breast Cancer Foundation’s 
(NBCF’s) research investment.
Design and participants:  Surveys based on the Payback Framework were sent 
to chief investigators involved in research funded by the NBCF during 1995–
2012; a bibliometric analysis of NBCF-funded publications in 2006–2010 was 
conducted; and a purposive, stratified sample of case studies was obtained.
Main outcome measures:  Research impact on knowledge production, the 
research system, informing policy, product development and broader health and 
economic benefits.
Results:  Of 242 surveys sent, 153 (63%) were returned. The average impact 
of journals in which NBCF publications appeared was double that of world 
Abstractrange of impacts across its research
investment portfolio. It is the first
study of its kind of a program of breast
cancer research.
• interaction with the potential end
users and beneficiaries of research,
which increases the scientific and
broader impacts of research;13,14
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p grants. ◆• research training and career
advancement;
• capacity building and critical mass
to undertake effective research;
• translation of research into clinical
practice, evident in changes to health
service policy and decision making
and best practice in diagnosis and
treatment;
• development of drugs, prognostic
tools or diagnostic technologies;
• actual health gain, which is often
hard to show, but may be evidenced in
changes in the behaviour or practice
of health care staff, consumers or the
public.
Data sources
Data held by the NBCF
Archival material that was made
available comprised a database with
descriptive information about all
NBCF grants, a database of publica-
tions linked to NBCF grants, and cop-
ies of grant proposals, annual reports
and end-of-grant reports for the case
studies.
Survey of chief investigators
A questionnaire was structured
around the multidimensional catego-
risation of impacts in the Payback
Framework. It also investigated fac-
tors influencing the dissemination
and utilisation of research. A total of
242 surveys were sent to the chief
investigators (CIs) involved in current
and previously awarded grants. This
excluded grants that had not yet
started or had recently commenced
and CIs who were unavailable for per-
sonal reasons.
Case studies
Sixteen case studies were conducted
to provide validation of data collected
from the survey and to supply richer
information about the full extent of
wider impacts of NBCF research. The
HERG compiled a shortlist of poten-
tial case studies based on reported
high impact in at least one of the
Payback categories in the CI survey
and high-impact project publications
identified in Elsevier’s Scopus data-
base. The case studies were selected
using a purposive, stratified approach
to ensure all Payback categories were
represented across the range of grant
types funded.
Each case study included document
and archival review, citation analysis,
searches for citations in clinical prac-
tice guidelines, and semi-structured
telephone interviews with CIs. Each
case study was described in a narra-
tive account organised according to
the stages of the Payback model, and
sent to CIs for final validation. All CIs
gave informed consent to participate
in the study, and approved the narra-
tive accounts.
Bibliometric analysis
Bibliometric analysis of the scientific
impact of recent NBCF-linked publi-
cations was conducted. This used an
existing database of publications from
Elsevier’s Scopus citation index devel-
oped to analyse the impact of research
conducted by the Victorian Compre-
hensive Cancer Centre (VCCC).
Approval was obtained from Elsevier
and VCCC for its use in this study.
The publication window was the 5-
year period 2006 to 2010. Two hun-
dred and sixty-two NBCF publications
were identified. The citation window
was 1 January 2006 to 1 May 2011.
Elsevier calculated world and Austral-
ian benchmarks for aggregate citation
rates, and thresholds to identify
highly cited journal articles.
Results
The response rate for the CI surveys
was 63% (153/242). For numbers of
not sent, not delivered and non-
returned surveys, see Appendix 1
(online at mja.com.au). The mean
grant start date of non-returned sur-
veys was in the range 2004–2005 and
returned surveys reported on grants
that started in the range 2006–2007.
The mean individual value of grants
related to returned surveys was
$348 096, compared with $170 203 for
those related to non-returned surveys.
The grants covered by survey
responses represented $53 million
(66%) of NBCF expenditure.
2 Distribution of the 153 grants covered by survey responses, by research type and 
end year of funding
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grants reported in survey responses, by m
and research type, 1995–2012, and by Co
Outline (CSO) classification, 2000 onwa
All NBC
grants, no
Funding mode n = 31
Research projects 231 (74%
Fellowships 38† (12%
Doctoral scholarships 30‡ (10%
National resources 14 (4%
Research type
Applied 125 (40
Basic 177 (57%
Equipment 11 (3%
CSO classification n = 22
Biology 54 (25%
Aetiology 22 (10%
Prevention 11 (5%
Early detection, diagnosis, 
prognosis
37 (17%
Treatment 26 (12%
Cancer control, survivorship and 
outcomes research
51 (23%
Scientific model systems 18 (8%
* Since 2000, NBCF has classified all grants awarde
International Cancer Research Partnership’s Commo
† Includes three top-up grants. ‡ Includes two top-u215MJA 200 (4) · 3 March 2014
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A: Novel approaches t
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E: A twin study of mam
and the risk of breast 
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like breast cancer
G: Investigation of the
in mammary gland de
prolactin receptor kno
H: Nanoscaled biosen
signatures to improve
treatment
I: Novel strategies for p
advanced breast canc
based biosensors
J: Multiple perspective
post-cancer, leading t
evaluation of supporti
K: Identification of new
metastatic breast can
L: Physical activity and
research to reality
M: Physical rehabilitat
N: Breast cancer and p
concurrent or subsequ
cancer diagnosis, man
O: The fertility and me
needs of younger wom
cancer
P: Breast cancer biospIn the survey data, the balance of
funding mechanisms and of applied
and basic research was representative
of the NBCF’s investment portfolio, as
was the focus according to Common
Scientific Outline (CSO) classification,
except for a slight underrepresentation
of “Biology” and overrepresentation of
“Cancer control, survivorship and out-
comes research” (Box 1).
The mean end year of grants cov-
ered by the surveys was in the range
2008–2009, compared with 2007 for all
NBCF grants awarded between 1995
and 2012. Of the grants evaluated, 111
(73%) ended from 2008 onwards, and
42 (27%) of all surveyed grants were
still in progress when the survey was
administered (Box 2).
Case study data provided illustra-
tions of high impact for each Payback
category (Box 3). Three case studies
are outlined in more detail in Box 4.
Knowledge production
Publications
The bibliometric study found that
between 2006 and 2010, the relative
citation impact of the 262 NBCF-
linked publications was 2.03, double
the world benchmark (1.0) and
exceeding the Australian average
(1.40). The journals in which NBCF-
linked publications were cited had an
impact of double the world average.
The analysis also found almost double
the expected number of NBCF publi-
cations among the most cited articles
(12 in the top 5%).
Dissemination
NBCF grant holders had made con-
siderable efforts to disseminate the
knowledge produced to academic and
non-academic audiences (Appendix
2; online at mja.com.au). Case studies
showed that the findings of NBCF
research were broadcast in Australia
and internationally through a wide
variety of platforms, thereby contrib-
uting to the pool of global scientific
knowledge, supplying an evidence
base for consumer groups, policymak-
ers and clinical practice, and also rais-
ing community awareness of breast
cancer and related concerns.
Interaction with research users
Data on interaction with research
users can be found in Appendix 3
(online at mja.com.au).
Research system
Research training and career 
development
As a direct consequence of the NBCF
grant, 185 higher degrees were gained
or expected, including 121 PhDs, and
almost half of CI surveys (70 [46%])
reported career progression for at
e studies and high impact Payback categories
Research 
type Funding Duration Cost Payback categories
owards targeting normoxic 
sue
Basic Novel concept award 24 months (2011–13) $185 200 Product development
d BRCA2 mutations in the 
ncer Study
Basic Priority-driven 
collaborative cancer 
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35 months (2008–11) $200 000 Practice/behaviour
nd evaluation of a menopause 
ung women after breast 
Applied Novel concept award 36 months (2005–08) $119 784 Policy/decision making
east cancer management 
 health outcomes
Applied Project grant 36 months (2000–03) $137 045 Health/health service
mographic breast density 
cancer
Applied Project grant 24 months (1996–98) $180 000 Knowledge production; research 
system
 for the treatment of basal- Basic Novel concept award 24 months (2011–13) $200 000 Product development
 role of the prolactin receptor 
velopment and cancer using 
ckout mice
Basic Project grant 24 months (1997–99) $183 101 Knowledge production
sors: reading epigenetic 
 breast cancer diagnosis and 
Basic Priority-driven 
collaborative cancer 
research scheme
36 months (2008–11) $400 000 Research system; product 
development
rediction and control of 
er via nanoscaled epigenetic-
Basic National collaborative 
breast cancer 
research grant 
program
60 months (2008–13) $5 000 000 Knowledge production; research 
system; product development; 
health/health service
s on sexuality and intimacy 
o the development and 
ve interventions
Applied Australian research 
council linkage grant
48 months (2008–12) $90 000 Research system; policy/
decision making; practice/
behaviour; health/health service
 therapeutic targets for 
cer
Basic Career fellowship 60 months (2009–2013) $995 720 Knowledge production; research 
system; product development
 breast cancer recovery: Applied Postdoctoral training 
fellowship
48 months (2005–09) $260 000 Policy/decision making
ion following breast cancer Applied Career fellowship 48 months (2009–13) $1 000 000 Practice/behaviour; health/
health service
regnancy: how does a 
ent pregnancy affect breast 
agement and outcomes?
Applied Doctoral research 
scholarship
24 months (2006–08) $61 200 Policy/decision making; 
practice/behaviour; health/
health service
nopause-related information 
en with a diagnosis of breast 
Applied Doctoral research 
scholarship
36 months (2002–2004) $76 800 Knowledge production; health/
health service
ecimen resource Applied Enabling grant 36 months (2005–08) $380 000 Research system(4) · 3 March 2014
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Capacity building
The surveyed CIs reported that 101
grants (66%) generated tools for
future research that would help to
build capacity across the research sys-
tem, such as new or significantly
improved animal models, cell lines,
physiological or biochemical markers,
assays, models of disease, or validated
patient questionnaires.
Targeting further research and attracting 
further income
The NBCF’s research investment of
$53 million in the surveyed grants had
generated significant opportunities to
attract further funding totalling $74.5
million: for every dollar the NBCF
invested, research teams leveraged an
additional $1.40.
Informing policy development
The survey found that 15 applied
grants had impacted on policy and 32
expected to do so, compared with one
basic research grant impacting on pol-
icy and 13 expecting to do so. Data on
actual and expected wider impacts
can be found in Appendix 4 (online at
mja.com.au).
Informing product development
Ten basic grants and four applied
grants had led to product development
of drugs, prognostic tools or diagnostic
technologies. Three applied research
projects had informed a broader spec-
trum of product development; for
example, development of a decision
aid, a psychological treatment protocol
and a sports bra.
Health gain and broader economic 
benefits
The survey results showed that
applied research grants had made the
largest contribution to changes in
behaviour or practice, with 20 applied
grants having realised impacts and 41
expecting to do so, compared with
two and 18 basic grants, respectively.
Discussion
This assessment was based on infor-
mation collected from 153 of 242
completed CI surveys (63%), a com-
paratively good response rate on
which to base valid conclusions.15 The
surveys were broadly representative of
the whole NBCF portfolio in terms of
grant mechanisms, balance of applied
and basic research, and areas of focus
(determined by CSO coding). Non-
returned surveys tended to relate to
grants that were older and smaller
than those covered in the completed
surveys, being on average 2 years
older and half the value.
The relatively short time frame that
had elapsed since many of the sur-
veyed grants had been awarded or
completed, with a demonstrable bias
of returned surveys towards grants
awarded in recent years, may have lim-
ited the assessment of impact, as most
grants were yet to realise their promise.
This was especially the case for basic
research, for which downstream
impacts take longer to accrue.14
The study also relied on subjective
reporting of impacts in CI survey
responses and case study interviews.
However, multiple data collection
approaches allowed comparisons to
be made with objective measures such
as citation data on the scientific
impact of publications, or the impact
of research on policy or practice in the
form of citations in clinical practice
guidelines. Interestingly, triangulation
of data sources showed that in sur-
veys, if anything, CIs tended to under-
report the impact of their research, as
has been noted in previous studies.4,15
While taking these potential limita-
tions into account, this study, none-
theless, found a wide range of impacts
across the Payback categories from
citations through to informing policy
— consistent with the NBCF’s invest-
ment in breast cancer research across
the whole spectrum of the disease. It
found that a mixed portfolio of
research areas and mechanisms
favoured a broad range of impacts.
Because the NBCF is a community-
funded organisation, a focus on gen-
erating health benefits to those
impacted by breast cancer is particu-
larly important. The evaluation found
that applied research was effective in
producing changes in policy and in
the behaviour and practice of health
care professionals, consumers and the
public; thus generating wider health
and health sector benefits, such as
improvements in service delivery. The
study found that basic research was
more closely linked to impacts relat-
ing to knowledge production, and to
product development in terms of
developing drugs, prognostic tools or
diagnostic technologies. It also high-
lighted that the funding of shared
resources such as biobanks and other
infrastructure was highly valuable to
the research system for both basic and
applied research.
The 16 case studies validated the
survey data and provided rich illustra-
tions of the full range of impacts.
The study builds on previous pub-
lished examples of Australian research
funding evaluations7,8 by adopting a
more systematic, multidimensional
and comprehensive approach. This is
the first Payback study of a program of
breast cancer research. Except for the
separately commissioned bibliometric
analysis, there are no benchmarking
data for comparing the impacts with
those of other breast cancer research
organisations; however, this study
creates a baseline for the future.
Research supported by the NBCF
attracted funds from other sources,
such as state-based Cancer Councils,
Cancer Australia and the National
4  Case studies
Case Study G
• The aim of the grant was to define the rol
mammary gland development
• 15 journal articles 1997–1999 (808 citatio
• The prolactin receptor knockout mouse d
widely used model in endocrinology
• Provided key preclinical model efficacy da
development of antiprolactin receptor an
treatment of breast cancer
• Drug development by multinational pharm
company now in Phase II clinical trials
Case Study L
• The aim of the grant was to investigate th
activity in enhancing functional capacity a
among breast cancer survivors
• 16 journal articles (289 citations)
• > 10 presentations to practitioners and co
• Informed three different sets of clinical pr
issued by professional associations in Aus
• Findings adopted in clinical practice
• Key public health gain is recognition that 
concerns exist for breast cancer survivors
quality of life
Case Study P
• The Australian Breast Cancer Tissue Bank
research-enabling infrastructure. The Nat
Cancer Foundation grant provided for col
blood and clinical data from newly diagno
breast cancer; distribution of biospecimen
to Australian researchers; support of tran
• 5200 donors, > 100 000 biospecimens co
samples accessed by researchers
• Around 30 organisations engaged with AB
• Instrumental in 20 research teams obtain
from Mayo Clinic (USA) to Canberra Hosp217MJA 200 (4) · 3 March 2014
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cil, and direct attribution of impacts to
particular funders is complex.
This study is particularly timely as
there is increasing pressure on both
government and non-government
research funders to provide evidence of
the wider impacts of research. There is
a renewed focus in the university sec-
tor on assessing the wider impacts of
research, with trials of a proposed new
initiative, Excellence in Innovation for
Australia (EIA), having recently been
completed. Many proponents hope to
see EIA sitting alongside the existing
Excellence in Research for Australia
framework for assessing academic
research performance.
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